Skip to main content
TipRanks
Go Ultimate75% OFF

Perseus Proteomics, Inc. (4882) AI Stock Analysis

1 Followers
JP:4882

Perseus Proteomics, Inc.

(TSE/TYO:4882)

Select Model
Rating:48Neutral
Price Target:JPY 125.00â–²(4.17% Upside)
Action:reiterated
Date:09/09/26

The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and declining equity—despite solid revenue growth and a debt-free balance sheet. Technicals are moderately supportive in the short term (positive MACD and price above short-term averages), but the longer-term trend remains weak. Valuation is constrained by negative earnings and the absence of dividend support.

Positive Factors
Sustained Revenue GrowthRevenue has nearly doubled across the reported period and continued to grow in 2026, demonstrating that the business is expanding its sales base despite ongoing losses. Continued top-line growth can improve operating leverage over time if the company converts scale into narrower operating deficits.
Negative Factors
Persistent Operating LossesDeep and persistent EBIT and net losses show that the current revenue base is not yet sufficient to cover operating costs. Even with year-over-year improvement in 2026, continued unprofitability limits internal funding capacity and leaves the business exposed if progress toward breakeven slows.

Perseus Proteomics, Inc. (4882) vs. iShares MSCI Japan ETF (EWJ)

-80%-60%-40%-20%0%20%40%JP:4882-59.60%EWJ+16.02%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 2.08B
Dividend Yield
―
Average Volume (3M)
475.49K
Price to Earnings (P/E)
-2.5
Beta (1Y)
1.68
Revenue Growth
4.28%
EPS Growth
15.93%
Country
Japan
Employees
35
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - General

Perseus Proteomics, Inc. Business Overview & Revenue Model

Company Description

Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alo...

How the Company Makes Money

null

Perseus Proteomics, Inc. Financial Statement Overview

Summary

Strong multi-year revenue growth and a debt-free balance sheet are positives, but the financial profile is dominated by deeply negative EBIT/net income and persistent negative operating and free cash flow. Equity has also declined materially over time, indicating ongoing value erosion despite some recent improvement in losses and cash burn.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue147.22M135.51M120.38M100.40M94.20M71.93M
Gross Profit126.49M116.16M104.05M87.69M86.53M67.75M
EBITDA-744.74M-715.80M-899.49M-1.10B-779.36M-594.14M
Net Income-744.64M-718.11M-904.80M-1.10B-787.00M-599.02M
Balance Sheet
Total Assets1.67B1.62B1.82B1.69B2.57B3.30B
Cash, Cash Equivalents and Short-Term Investments1.59B1.52B1.67B1.54B2.44B3.21B
Total Debt000000
Total Liabilities442.44M405.77M386.43M295.46M170.10M148.38M
Stockholders Equity1.22B1.22B1.43B1.40B2.40B3.15B
Cash Flow
Free Cash Flow0-662.83M-794.64M-976.90M-734.82M-510.71M
Operating Cash Flow0-653.33M-719.49M-833.90M-564.27M-476.84M
Investing Cash Flow0-10.06M-75.16M-150.34M-212.99M-33.87M
Financing Cash Flow0497.33M923.38M63.94M-20.00K2.65B

Perseus Proteomics, Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price120.00

Price Trends

50DMA150.38Negative
100DMA150.07Negative
200DMA182.05Negative

Market Momentum

MACD-8.02Positive
RSI33.03Neutral
STOCH29.46Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4882, the sentiment is Negative. The current price of 120.00 is below the 20-day moving average (MA) of 134.75, below the 50-day MA of 150.38, and below the 200-day MA of 182.05, indicating a bearish trend. The MACD of -8.02 indicates Positive momentum. The RSI at 33.03 is Neutral, neither overbought nor oversold. The STOCH value of 29.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4882.

Perseus Proteomics, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4882 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:6090JP:609068NeutralJPY 3.32B10.62―3.21%7.98%61.76%
JP:3386JP:338667NeutralJPY 7.02B20.86―4.13%7.17%36.23%
JP:7707JP:770762NeutralJPY 5.40B11.46―1.03%9.27%―
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4882JP:488248NeutralJPY 2.21B-2.50――4.28%15.93%
JP:2342JP:234244NeutralJPY 3.32B-178.76――8.53%97.93%
JP:4978JP:497842NeutralJPY 11.43B-24.60――-8.23%-48.10%

* General Sector Average

Performance Comparison

-50%0%50%100%150%JP:4882JP:2342JP:3386JP:4978JP:6090JP:7707Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4882 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4882Perseus Proteomics, Inc.120.00-179.00-59.87%
JP:2342Trans Genic Inc.197.004.002.07%
JP:3386Cosmo Bio Co., Ltd.1212.00-155.54-11.37%
JP:4978ReproCELL Inc.107.00-53.00-33.13%
JP:6090Human Metabolome Technologies, Inc.560.00-72.49-11.46%
JP:7707Precision System Science Co.,Ltd195.00-7.00-3.47%

Perseus Proteomics, Inc. Corporate Events

Perseus Proteomics Recognizes Non-operating Items and Impairment Loss

Nov 13, 2026

Perseus Proteomics Inc. announced that, for the six months ended September 30, 2026, it recognized non-operating income comprising subsidy income of 19,316 thousand yen, insurance income of 10,000 thousand yen, and interest income of 3,329 thousand y...

Perseus Proteomics Reports Six-Month Results Without FY2027 Forecast

Nov 13, 2026

Perseus Proteomics Inc., listed on the Tokyo Stock Exchange, reported net sales of ¥52 million for the six months ended September 30, 2026, down 13.7% year over year, while operating, ordinary and net losses were ¥411 million, ¥394 million and ¥399 m...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 09, 2026